Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
POUT: Phase III randomised trial of perioperative chemotherapy vs surveillance in upper tract urothelial cancer

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.18
Views: 1459

Dr Alison Birtle - Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK

Dr Birtle speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the results of the POUT study that addresses whether adjuvant chemotherapy improves disease free survival for patients with histologically confirmed pT2-T4 N0-3 M0 upper tract urothelial cancer.

She goes on to state that at the time of interim analysis, median follow-up was 17.6 months and grade ≥3 toxicities were reported in 60% chemotherapy patients and 24% surveillance patients.

Dr Birtle then goes on to discuss the results of the study, highlighting that adjuvant chemotherapy improved disease free survival and progression free survival in the upper tract urothelial cancer patient cohort.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation